Pharma BD Deal Intelligence
AbbVie's $9.8B acquisition of Stemcentrx for anti-DLL3 ADC Rova-T in small cell lung cancer collapsed entirely, with three failed Phase 3 trials (TRINITY, TAHOE, MERU) triggering a $4B impairment in 2019. The program was terminated the same year, wiping out essentially the full value of the deal and cutting 178 Stemcentrx-linked jobs.
AbbVie's ~$5.8-9.8B bet on Rova-T collapsed entirely — three failed Phase 3 trials, ~$5B in impairment charges, program terminated in 2019, zero commercial return.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
GEN reported the up-to-$9.8B Stemcentrx acquisition framed as AbbVie's bet on Rova-T and the Stemcentrx cancer stem cell discovery platform; many analysts felt…
FierceBiotech: AbbVie takes a $4B impairment on Rova-T failures, validating earlier skepticism that paying $5.8B upfront for an unproven late-stage ADC was…
Pharmaphorum's retrospective: Rova-T became a textbook case of a 'multi-billion dollar failure' — overpriced biotech M&A, Phase 1/2 data over-extrapolated, and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AbbVie acquired South San Francisco-based Stemcentrx for ~$5.8B (approximately $2B cash + $3.8B AbbVie stock) plus up to $4B in success-based milestones (~$9.8B total). Lead asset Rova-T was an anti-DLL3 ADC in registrational trials for SCLC. Acquisition recorded $4B impairment in 2018-2020 after Phase 3 failures; program ultimately terminated.
AbbVie's ~$5.8-9.8B bet on Rova-T collapsed entirely — three failed Phase 3 trials, ~$5B in impairment charges, program terminated in 2019, zero commercial return.
Assessment window: 5yr post-close.
30K US cases/yr
Small cell lung cancer is an aggressive neuroendocrine lung cancer accounting for ~13% of US lung cancer diagnoses, with most patients presenting at extensive (metastatic) stage. It grows rapidly, responds initially to platinum-etoposide chemotherapy, then almost universally relapses with limited second-line options. Median overall survival is ~7 months and the disease has not seen a true paradigm shift in decades — the modest gains from PD-L1 inhibitor add-on (atezolizumab, durvalumab) approved 2018-2019 came after this deal closed.
At deal time (April 2016), the SCLC standard of care was platinum-etoposide chemotherapy with topotecan in second line — no targeted therapy had ever been approved and no biomarker-selected therapy existed. Rova-T was positioned as the first DLL3-targeted antibody-drug conjugate, with Phase 1/2 data showing 44% ORR in DLL3-high relapsed patients; AbbVie projected $5B peak sales. The thesis collapsed across three Phase 3 readouts: TRINITY (3L) showed only 16% ORR in 2018, TAHOE (2L) was halted in Dec 2018 with shorter survival than topotecan, and MERU (1L maintenance) was terminated by an IDMC in Aug 2019 for futility. AbbVie wrote off ~$4B of the $5.8B upfront and the program was discontinued; the SCLC innovation gap was subsequently filled by atezolizumab+chemo (Tecentriq, Genentech, IMpower133) and durvalumab+chemo (Imfinzi, AstraZeneca, CASPIAN), with newer DLL3-bispecifics (tarlatamab/Imdelltra, Amgen, approved 2024) finally validating DLL3 as a tractable target with a different modality.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Stemcentrx Inc. (this deal) | 2016 | $9.8B | 9 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2016 deals · AbbVie Inc. deals · Oncology deals